GlassScriptPhysician profile
James D Stockstill
NPI 1063494748
$3,350.31
in general payments reported to CMS, 2019-2025
25 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $499 · 2021: $700 · 2022: $256 · 2023: $464 · 2024: $385 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.79 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $756.36 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $300.96 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.48 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $293.32 | 2021-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $254.33 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $247.95 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $164.12 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $161.22 | 2019-2022 | |
| Pfizer INC. | $150.03 | 2019-2024 | |
| Abbvie INC. | $147.10 | 2021-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $95.65 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $89.27 | 2019-2023 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.64 | 2020-2021 | |
| Exact Sciences Corporation | $48.71 | 2023-2024 | Cologuard Collection Kit |
| Ardelyx, INC. | $46.65 | 2024 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $35.51 | 2023-2024 | Arexvy, Shingrix |
| Allergan, INC. | $28.47 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $27.05 | 2021 | |
| Ibsa Pharma INC. | $23.64 | 2024 | Tirosint, Licart |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Astellas Pharma US INC | $19.39 | 2023 | Veozah |
| Viatris Specialty LLC | $17.50 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $14.72 | 2025 | Evkeeza |
| Takeda Pharmaceuticals U.S.A., INC. | $14.39 | 2019 | |
| Eisai INC. | $13.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stockstill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.